Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers

Biopharma companies are constantly combating patent expirations. But three large drugmakers in particular will be the most negatively impacted from expected exclusivity losses by 2030.

Among 19 large U.S. and European biopharma companies, Bristol Myers Squibb, Amgen and Pfizer will face two major issues. All three companies will have a large portion of their 2025 revenues exposed to generic or biosimilar competition, and they will also see those revenues erode quickly, an SVB Leerink team led by analyst Geoffrey Porges said in a Monday note to clients.